Health Care

Analyst Stock Ratings: Exact Sciences Corporation (EXAS), Air Lease Corporation (AL)

Therefore 59% are positive. Exact Sciences Corporation has a fifty-two week low of $13.05 and a fifty-two week high of $63.60. Exact Sciences Corporation has an average rating of "Buy" and a consensus price target of $49.98. EXACT Sciences had 57 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by Lake Street with "Hold" on Tuesday, November 24. The company was initiated on Friday, December 18 by BTIG Research. Jefferies maintained it with "Buy" rating and $55.0 target in Friday, October 20 report. The company was maintained on Monday, August 24 by Canaccord Genuity. As per Tuesday, October 6, the company rating was maintained by Roth Capital. Perceptive Limited Company holds 0.18% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS) for 100,000 shares. Goldman Sachs maintained the shares of EXAS in report on Tuesday, October 6 with "Neutral" rating. The firm earned "Neutral" rating on Wednesday, May 4 by Mizuho. The company has market cap of $.

Currently, the stock carries a price to earnings ratio of 12.59, a price to book ratio of 1.22, and a price to sales ratio of 2.98. The Firm operates through three divisions: Asia, Latin America and North America/Europe. BTIG Research maintained EXACT Sciences Corporation (NASDAQ:EXAS) rating on Monday, July 17. The lowest target is $78.0 while the high is $90.0. A P/B ratio of less than 1.0 can indicate that a stock is undervalued, while a ratio of greater than 1.0 may indicate that a stock is overvalued. MJN was included in 4 notes of analysts from October 28, 2016. Buys Exact Sciences Corp, Hawaiian Holdings Inc ..." published on November 02, 2017 as well as's news article titled: "Earnings Reaction History: "EXACT Sciences Corporation, 36.4% Follow-Through ..." with publication date: "October 30, 2017. Bank of America has "Buy" rating and $56 target. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) has "Equal-Weight" rating given on Thursday, February 25 by Stephens. It has underperformed by 16.70% the S&P500. Morgan Stanley holds 0.01% or 1.25M shares in its portfolio. Commonwealth Equity Svcs owns 17,723 shares or 0% of their U.S. portfolio. Prudential Financial Inc. now owns 89,069 shares of the medical research company's stock valued at $4,197,000 after buying an additional 76,910 shares during the period. The Pennsylvania-based Glenmede Trust Co Na has invested 0.01% in the stock.

ILLEGAL ACTIVITY NOTICE: "Traders Buy High Volume of Put Options on Exact Sciences Corporation (EXAS)" was reported by StockNewsTimes and is owned by of StockNewsTimes. About 340 shares traded. The company's quarterly EPS surprised Wall Street by as much as 500% to the upside in its last earnings announcement, so investors should note this tendency when assessing consensus estimates.

Exact Sciences Corporation is a molecular diagnostics company.

In the most updated research from a number of analysts on Wall Street, the company gets 7 Buys and 0 Sell among 7 analysts. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer.

Investors sentiment increased to 1.27 in Q2 2017. Its up 0.28, from 0.99 in 2017Q1.

Exact Sciences Corporation (NASDAQ:EXAS) ended its day at $60.37 with the rising stream of 2.01% and its total traded volume was 1.35 million shares less than the average volume.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ameriprise Fincl Incorporated, a Minnesota-based fund reported 238,824 shares. Prudential Financial Inc. boosted its position in shares of Exact Sciences Corporation by 3.0% in the 1st quarter. 29,782 were accumulated by Millennium Management Ltd Co. M&T Commercial Bank invested in 0% or 15,134 shares. Moreover, New York State Common Retirement Fund has 0.01% invested in EXACT Sciences Corporation (NASDAQ:EXAS) for 156,741 shares. The Illinois-based Alyeska Inv Gru Lp has invested 0.14% in EXACT Sciences Corporation (NASDAQ:EXAS). The stock of EXACT Sciences Corporation (NASDAQ:EXAS) has "Buy" rating given on Wednesday, June 7 by Canaccord Genuity. 17,723 are held by Commonwealth Equity Services. Us Bancorp De accumulated 250,933 shares or 0.03% of the stock. Sanctuary Wealth Advsrs Limited Liability invested in 3.21% or 103,849 shares. The correct version of this piece of content can be viewed at Kistler owns 315 shares. Finally, Jefferies Group LLC lifted their price objective on Exact Sciences Corporation to $60.00 and gave the stock a "buy" rating in a report on Tuesday, October 31st.

Like this


13 November 2017
Donald Trump Asks China for Help with UCLA, LiAngelo Ball Situation
White House press secretary Sarah Huckabee Sanders confirmed in an email that Trump raised the matter with Xi. The two leaders discussed North Korea's nuclear threat, bilateral trade relations and a host of other issues.

13 November 2017
TOWIE star's ex-boyfriend threw acid over London clubbers
Andre Phoenix - who was on trial alongside Collins - was acquitted at Wood Green Crown Court of all charges against him. He said he did not hand himself in to police because he feared Ms McCann would be targeted by gang members if he did .

13 November 2017
Iran sticks to key limits of nuclear deal -UN watchdog
Iran has remained within the essential limits on its nuclear activities imposed by its 2015 deal with six world powers, the United Nations atomic watchdog said in a report on Monday.

13 November 2017
Kiss Daniel Breaks Out Of G-Worldwide, Floats New Record Label
Daniel is widely regarded as underrated and under-celebrated, owing to the few and far between acclaim he receives for his work.

13 November 2017
MPs Will Get Final Say On Brexit Deal, Government Agrees In U-Turn
But if they reject the deal the Government strikes with the EU, Britain will instead leave the bloc with no deal, he confirmed. Mr Davis said the talks were expected to move on to discussing a future free trade agreement "as soon as possible".

13 November 2017
Nektar Therapeutics (NASDAQ:NKTR) Takes Off in Trading Today - Up by 18.83%
Following the acquisition, the director now directly owns 121,333 shares of the company's stock, valued at $1,637,995.50. Nektar Therapeutics has gapped open sharply higher Monday morning and is now up 8.38 at $40.88 on above average volume.

13 November 2017
Lam Research Corporation (LRCX) Shares Bought by Alps Advisors Inc
KeyBanc Capital Markets maintained Lam Research Corporation (NASDAQ:LRCX) on Wednesday, October 18 with "Buy" rating. (NYSE:HES). It worsened, as 43 investors sold LRCX shares while 255 reduced holdings. 110 funds opened positions while 182 raised stakes.

13 November 2017
Global Dental Consumables Market Size, Status and Forecast 2022
It also throws a light on cropping up products of Dental Floss industry, details of product price/cost and various market forces. It also features past and present market trends to figure out if there are any business opportunities and scope in upcoming era.

13 November 2017
Whitefish Gouge Worker Fees in Puerto Rico: Energy Experts
Last week, Rossello asked his cabinet to sign and submit undated letters of resignation , The New York Times reported . Prepa's grid is now working at 47 percent of its capacity, according to statistics from the Puerto Rican government.

13 November 2017
RPS Group plc (RPS) PT Raised to GBX 330 at Liberum Capital
In other news, insider Brian Gilvary purchased 70 shares of the business's stock in a transaction dated Monday, September 11th. The shares were acquired at an average price of GBX 446 ($5.87) per share, with a total value of £312.20 ($410.63).